Mall PA
GHK-Cu NOT FOR HUMANS CHECK BEFORE YOU COMPETE
File 04 · naturally occurring copper-binding tripeptide

GHK-Cu

Also called: copper peptide, copper tripeptide-1, glycyl-L-histidyl-L-lysine copper, Iamin (former wound-gel brand)

Gray areaLimited

GHK is a three-amino-acid peptide found in human plasma, saliva and urine that binds copper tightly; GHK-Cu is the copper complex. It is a common ingredient in skin-care products and has been studied for wound healing and skin remodeling.

Why the gym talks about it

It is popular in the looks-and-longevity corner of gym culture for skin, hair and 'collagen', and it shows up in recovery blends alongside BPC-157 and TB-500.

What the research actually found

  • animal (rat)In rats with ischemic (poor blood flow) open wounds, a topical GHK-Cu gel sped wound closure and lowered inflammatory markers (TNF-alpha, MMP-2, MMP-9) compared with controls. Source
  • in vitro / gene-expression data (review)Gene-expression analyses suggest GHK can shift the activity of many human genes tied to tissue remodeling and antioxidant defense. These are computational and cell-based findings from a research group closely tied to the compound. Source
  • small human cosmetic studies (topical)Reviews describe small cosmetic studies in which topical GHK-Cu creams improved measures of skin appearance; most are older, small and not independently replicated. Source
  • small human trial (topical)In a small randomized study after CO2 laser skin resurfacing (13 completers), GHK-Cu skin care did not objectively improve redness, wrinkles or skin quality, although patients using it reported higher satisfaction. Source

Human evidence: limited. There are small topical skin studies with mixed results; there are no published controlled trials of injected GHK-Cu.

Tested lifters

Not named on the 2026 Prohibited List. Some analysts note injectable use could fall into a gray zone under catch-all language, but no specific listing exists.

Uncertain. Topical skin-care use is generally regarded as low risk. Injectable 'research' GHK-Cu is not explicitly banned, but tested lifters should check with Global DRO or USADA before relying on that. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

FDA status

Not FDA-approved as a drug (it is a common cosmetic ingredient). FDA had GHK-Cu for injectable routes in Category 2 of the interim 503A list; it was removed from Category 2 in the April 15, 2026 action. FDA's May 14, 2026 categories list shows 'GHK-Cu (except for injectable routes of administration)' reinstated to Category 1 on May 5, 2026, so non-injectable compounding falls under the interim policy. FDA plans to consult the advisory committee on GHK-Cu before the end of February 2027.

As of 2026-10-01.

Known and theoretical risks

  • FDA cites possible immune reactions from aggregation and peptide impurities for injectable GHK-Cu, and notes limited human data. Source
  • Human safety data for injected GHK-Cu are essentially absent; topical data do not establish the safety of injection. Source

Quick answers

Is GHK-Cu banned for drug-tested lifters?

Not named on the 2026 Prohibited List. Some analysts note injectable use could fall into a gray zone under catch-all language, but no specific listing exists. Uncertain. Topical skin-care use is generally regarded as low risk. Injectable 'research' GHK-Cu is not explicitly banned, but tested lifters should check with Global DRO or USADA before relying on that. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

Is GHK-Cu FDA approved?

Not FDA-approved as a drug (it is a common cosmetic ingredient). FDA had GHK-Cu for injectable routes in Category 2 of the interim 503A list; it was removed from Category 2 in the April 15, 2026 action. FDA's May 14, 2026 categories list shows 'GHK-Cu (except for injectable routes of administration)' reinstated to Category 1 on May 5, 2026, so non-injectable compounding falls under the interim policy. FDA plans to consult the advisory committee on GHK-Cu before the end of February 2027.

How strong is the human evidence for GHK-Cu?

Limited. There are small topical skin studies with mixed results; there are no published controlled trials of injected GHK-Cu.

Sources

Research-use-only information file. Nothing here is medical advice or instructions for use. Not evaluated by the FDA. Talk to your doctor.

More files

Back to the basement